Modality
ERT
MOA
CGRPant
Target
JAK1
Pathway
Checkpoint
GBMMM
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
~Jul 2021
→ ~Oct 2022
Phase 3
Jan 2023
→ Sep 2027
Phase 3Current
NCT05690296
764 pts·MM
2023-01→2027-09·Completed
764 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-151.5y awayPh3 Readout· MM
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Complet…
Catalysts
Ph3 Readout
2027-09-15 · 1.5y away
MM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05690296 | Phase 3 | MM | Completed | 764 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |